GlassScriptPhysician profile
Jason Jacob
NPI 1659117570
$1,632.67
in general payments reported to CMS, 2019-2025
16 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $546 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $553.54 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $201.32 | 2024-2025 | Entyvio |
| Novo Nordisk INC | $122.67 | 2024-2025 | Ozempic, Rybelsus |
| Verona Pharma, INC. | $121.77 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.88 | 2024 | |
| Abbott Laboratories | $102.10 | 2024 | Freestyle Libre 3 |
| Actelion Pharmaceuticals US, INC. | $98.95 | 2025 | Opsumit, Uptravi |
| Amgen INC. | $96.05 | 2025 | Evenity |
| Janssen Biotech, INC. | $41.82 | 2025 | Rybrevant |
| Abiomed | $41.14 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $32.27 | 2024 | |
| Madrigal Pharmaceuticals | $24.41 | 2025 | Rezdiffra |
| Dexcom, INC. | $23.06 | 2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $21.55 | 2025 | Airsupra |
| E.R. Squibb & Sons, L.L.C. | $17.10 | 2025 | Camzyos |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $14.04 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Jacob listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.